Cure8 research brief
The study reports that kaempferol reduced inflammation, fibrosis, and barrier damage in mouse and cell models of colitis — mechanisms directly relevant to IBD progression and symptoms.
Researchers in IBD pathophysiology and drug discovery; clinicians following translational research; adult patients interested in experimental botanical-derived treatments (note: preclinical only).
The researchers used a 2% DSS chronic colitis mouse model and TNF-α–stimulated colonic epithelial and fibroblast cell co-cultures to test kaempferol (KF). In mice, KF-treated groups showed improvements in weight, disease activity index, colon length, and histology, plus reductions in inflammatory cytokines and oxidative stress markers.
In cell experiments, KF countered TNF-α effects on epithelial cells, reduced fibroblast activation, and the authors identify HMOX1 as important for the epithelial–fibroblast crosstalk affected by KF.
The work is preclinical: findings are from animal and in vitro experiments, not human trials, so clinical effects, dosing, or safety in people with IBD are not established. This paper appears in Frontiers in Pharmacology and the supplied text is an abstract-level summary of the experiments and results.
This article summarizes animal and in vitro experiments (abstract-level). Results do not translate directly to human treatment without clinical testing; safety, dosing, and efficacy in people are unknown.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This preclinical study links cod skin–derived collagen peptides to reduced colitis severity in mice through changes in the gut microbiota and suppression of the NLRP3 inflammasome — pathways that could be relevant to...
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study reports an experimental coating that both protects a probiotic and provides antioxidant, anti-inflammatory effects in a mouse colitis model—an approach that, if validated in humans, could improve probiotic...
